1. Home
  2. KRMD vs ZNTL Comparison

KRMD vs ZNTL Comparison

Compare KRMD & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KORU Medical Systems Inc. (DE)

KRMD

KORU Medical Systems Inc. (DE)

N/A

Current Price

$3.43

Market Cap

146.4M

Sector

Health Care

ML Signal

N/A

Logo Zentalis Pharmaceuticals Inc.

ZNTL

Zentalis Pharmaceuticals Inc.

N/A

Current Price

$1.37

Market Cap

165.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
KRMD
ZNTL
Founded
1980
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
146.4M
165.1M
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
KRMD
ZNTL
Price
$3.43
$1.37
Analyst Decision
Buy
Strong Buy
Analyst Count
4
11
Target Price
$6.13
★ $7.44
AVG Volume (30 Days)
173.2K
★ 1.3M
Earning Date
11-10-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 53.85
18.03
EPS
★ N/A
N/A
Revenue
★ $41,127,366.00
N/A
Revenue This Year
$17.24
N/A
Revenue Next Year
$16.13
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 22.23
N/A
52 Week Low
$2.86
$1.28
52 Week High
$6.61
$6.95

Technical Indicators

Market Signals
Indicator
KRMD
ZNTL
Relative Strength Index (RSI) 51.35 22.22
Support Level $3.00 N/A
Resistance Level $3.41 $1.98
Average True Range (ATR) 0.26 0.18
MACD 0.02 -0.01
Stochastic Oscillator 37.83 0.72

Price Performance

Historical Comparison
KRMD
ZNTL

About KRMD KORU Medical Systems Inc. (DE)

KORU Medical Systems Inc develops, manufactures, and commercializes large volume subcutaneous infusion solutions for the subcutaneous drug delivery market. Its product portfolio focuses on mechanical infusion devices, including the FREEDOM60 and FreedomEdge syringe drivers, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company operates as one segment. Its revenue streams are: Domestic Core, International Core and Pharma services and clinical trials. The majority of the company's revenue is derived from the Domestic Core business, which consists of sales of its syringe drivers, tubing and needles. Geographically, its revenues are predominantly derived from the United States.

About ZNTL Zentalis Pharmaceuticals Inc.

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

Share on Social Networks: